Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Aug 3, 2020 (6 years ago)

Pain Relief Maximum Strength

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Stability Specifications: Out-of-Specification (OOS) results for the Aspirin related compound Salicylic Acid was observed.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Pain Relief Maximum Strength (Acetaminophen 250 mg/aspirin 250 mg/Caffeine 65 mg) tablets, 2-tablets per packet, Manufactured for Select Corporation, Carrollton, TX 75007

Drug: Acetaminophen Category: Pain Relief & OTC Medication

Recalling firm
Ultra Seal Corporation
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1512-2020 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Acetaminophen recalls

See all
Class II · Moderate risk

Tylenol

Defective Container

Ongoing Packaging defect Kenvue Brands LLC D-0121-2026
Class II · Moderate risk

Acetaminophen 500mg Caffeine 65mg caplets

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Ongoing Labeling / mix-up Aero Healthcare NDC 55305-135-01 D-0155-2026

Other recalls by Ultra Seal Corporation

All 2020 recalls
Class II · Moderate risk

Sinus Relief

cGMP deviations

Terminated cGMP deviation Ultra Seal Corporation D-0518-2022